OCALA, Fla., April 04, 2025 (WORLD NEWSWIRE)– Objective ImmunoTech Inc. (” OBJECTIVE” or the “Business”) OBJECTIVE, an immuno-pharma business concentrated on the research study and advancement of rehabs to deal with numerous kinds of cancers, immune conditions and viral illness, consisting of COVID-19, reported that on April 4, 2025, it got alert from NYSE Guideline of the NYSE American LLC (the “NYSE American” or the “Exchange”) that it had actually suspended trading of the Business’s typical stock and of its decision to start delisting procedures of the Business’s typical stock from the Exchange pursuant to Area 1003( f)( v) of the NYSE American Business Guide due to the low asking price of the Business’s typical stock. The Business prepares to appeal the decision to the Exchange’s Listing Credentials Panel, although there can be no guarantee that any such appeal will achieve success.
The Business’s typical stock is anticipated to start trading on the Pink Free Market on April 7, 2025.
Extra information are consisted of in, and the description above is certified in its totality by, objective’s Present Report on Type 8-K submitted with the SEC on April 4, 2025, which will be offered under “Financiers”– “SEC Filings” at aimimmuno.com.
About Objective ImmunoTech Inc.
Objective ImmunoTech Inc. is an immuno-pharma business concentrated on the research study and advancement of rehabs to deal with numerous kinds of cancers, immune conditions and viral illness, consisting of COVID-19. The Business’s lead item is a first-in-class investigational drug called Ampligen ® (rintatolimod), a dsRNA and extremely selective TLR3 agonist immuno-modulator with broad spectrum activity in medical trials for worldwide essential cancers, viral illness and conditions of the body immune system.
For additional information, please visit aimimmuno.com and get in touch with the Business on X, LinkedIn, and Facebook.
Positive Declarations
This news release includes “positive declarations” within the significance of Area 27A of the Securities Act of 1933, as changed, and Area 21E of the Securities Exchange Act of 1934, as changed, consisting of, however not restricted to, declarations that are based upon management’s existing expectations, presumptions, price quotes, forecasts and beliefs. Using words such as, however not restricted to, “expect,” “think,” “continue,” “could,” “quote,” “anticipate,” “plan,” “may,” “might,” “strategy,” “possible,” “forecast,” “job,” “should,” “target,” “will,” or “would” and comparable words or expressions are planned to determine positive declarations. These declarations consist of, however are not restricted to, declarations relating to the Business’s objective to gain back compliance with the listing requirements of the NYSE American and its capability to do so. These declarations include threats, unpredictabilities and other elements that might trigger real outcomes or accomplishments to be materially various and negative from those revealed in or indicated by the positive declarations. The Business advises financiers to think about particularly the numerous threat elements recognized in its newest Type 10-K, and any threat elements or cautionary declarations consisted of in any subsequent Type 10-Q or Type 8-K, submitted with the U.S. Securities and Exchange Commission. The positive declarations consisted of herein speak just since the date hereof, and the Business presumes no responsibility to upgrade any positive declarations, whether as an outcome of brand-new details, subsequent occasions or otherwise, other than as needed by law.
Financier Contact: JTC Group, LLC Jenene Thomas 908.824.0775 AIM@jtcir.com
Momentum 5.45
Development–
Quality–
Worth 6.98
Market News and Data gave you by Benzinga APIs